Medication Management for Postpartum OCD

First-Line Pharmacological Approach

The American College of Obstetricians and Gynecologists recommends starting with SSRIs at higher doses than used for depression, as OCD requires substantially higher dosing to achieve therapeutic effect 1, 2
Maintain the maximum recommended or tolerated SSRI dose for a minimum of 8-12 weeks before declaring treatment failure 1, 2
All SSRIs demonstrate similar efficacy for OCD; select based on side effect profile, drug interactions, and patient-specific factors 1, 3

The American Academy of Pediatrics recommends continuing SSRI therapy during breastfeeding as the benefits of treating maternal OCD typically outweigh theoretical risks to the infant 4, 5
SSRIs are generally compatible with breastfeeding, with most having relative infant doses (RIDs) below the 10% safety threshold 4
Monitor infants for irritability, feeding difficulties, or sleep disturbances, though adverse effects are uncommon 4, 5

The American Psychiatric Association recommends augmenting with atypical antipsychotics rather than switching to another SSRI when first-line SSRI monotherapy fails after adequate trial (8-12 weeks at maximum tolerated dose) 1, 2, 3
Aripiprazole is recommended for treatment-resistant cases, though approximately only one-third show meaningful response 2, 3

The American College of Psychiatrists recommends maintaining treatment for 12-24 months after achieving remission due to extremely high relapse rates with premature discontinuation 1, 2, 3
Consider monthly booster CBT sessions for 3-6 months after acute response to prevent relapse 3

The American Psychological Association recommends combining pharmacotherapy with CBT featuring exposure and response prevention (ERP) for optimal outcomes, as this combination produces larger effect sizes than medication alone 2, 3

The American Academy of Pediatrics recommends not discontinuing SSRIs during breastfeeding based on theoretical concerns alone, as untreated maternal OCD poses greater risks to infant development 4, 5
Do not use inadequate SSRI doses—OCD requires substantially higher doses than depression treatment 1, 2
Do not declare treatment failure before 8-12 weeks at maximum tolerated dose 1, 2

Monitor for SSRI adverse effects including gastrointestinal symptoms, sexual dysfunction, and activation 1
When using antipsychotic augmentation, monitor metabolic parameters, weight, and extrapyramidal symptoms 3
Assess infant development and feeding patterns if breastfeeding while on medication 4, 5